Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

References for PMC Articles for PubMed (Select 20418915)

1.

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.

Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, Fruman DA.

Nat Med. 2010 Feb;16(2):205-13. doi: 10.1038/nm.2091. Epub 2010 Jan 13.

2.

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.

Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, Vincent JP, Ellston R, Jones D, Sini P, James D, Howard Z, Dudley P, Hughes G, Smith L, Maguire S, Hummersone M, Malagu K, Menear K, Jenkins R, Jacobsen M, Smith GC, Guichard S, Pass M.

Cancer Res. 2010 Jan 1;70(1):288-98. doi: 10.1158/0008-5472.CAN-09-1751. Epub 2009 Dec 22.

3.

mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling.

Julien LA, Carriere A, Moreau J, Roux PP.

Mol Cell Biol. 2010 Feb;30(4):908-21. doi: 10.1128/MCB.00601-09. Epub 2009 Dec 7.

4.

An emerging role of mTOR in lipid biosynthesis.

Laplante M, Sabatini DM.

Curr Biol. 2009 Dec 1;19(22):R1046-52. doi: 10.1016/j.cub.2009.09.058. Review.

5.

mTOR and cancer: many loops in one pathway.

Efeyan A, Sabatini DM.

Curr Opin Cell Biol. 2010 Apr;22(2):169-76. doi: 10.1016/j.ceb.2009.10.007. Epub 2009 Nov 27.

6.

Rictor is a novel target of p70 S6 kinase-1.

Treins C, Warne PH, Magnuson MA, Pende M, Downward J.

Oncogene. 2010 Feb 18;29(7):1003-16. doi: 10.1038/onc.2009.401. Epub 2009 Nov 23.

PMID:
19935711
7.

Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer.

Gulhati P, Cai Q, Li J, Liu J, Rychahou PG, Qiu S, Lee EY, Silva SR, Bowen KA, Gao T, Evers BM.

Clin Cancer Res. 2009 Dec 1;15(23):7207-16. doi: 10.1158/1078-0432.CCR-09-1249. Epub 2009 Nov 24.

8.

Targeting mTOR globally in cancer: thinking beyond rapamycin.

Shor B, Gibbons JJ, Abraham RT, Yu K.

Cell Cycle. 2009 Dec;8(23):3831-7. Epub 2009 Dec 14. Review.

9.

The target of rapamycin complex 2 controls dendritic tiling of Drosophila sensory neurons through the Tricornered kinase signalling pathway.

Koike-Kumagai M, Yasunaga K, Morikawa R, Kanamori T, Emoto K.

EMBO J. 2009 Dec 16;28(24):3879-92. doi: 10.1038/emboj.2009.312. Epub .

10.

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.

Yuan R, Kay A, Berg WJ, Lebwohl D.

J Hematol Oncol. 2009 Oct 27;2:45. doi: 10.1186/1756-8722-2-45. Review.

11.

mTOR signaling at a glance.

Laplante M, Sabatini DM.

J Cell Sci. 2009 Oct 15;122(Pt 20):3589-94. doi: 10.1242/jcs.051011. Review. No abstract available.

12.

Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1.

Dibble CC, Asara JM, Manning BD.

Mol Cell Biol. 2009 Nov;29(21):5657-70. doi: 10.1128/MCB.00735-09. Epub 2009 Aug 31.

13.

The double-edged sword of autophagy modulation in cancer.

White E, DiPaola RS.

Clin Cancer Res. 2009 Sep 1;15(17):5308-16. doi: 10.1158/1078-0432.CCR-07-5023. Epub 2009 Aug 25. Review.

14.

Targeting the phosphoinositide 3-kinase pathway in cancer.

Liu P, Cheng H, Roberts TM, Zhao JJ.

Nat Rev Drug Discov. 2009 Aug;8(8):627-44. doi: 10.1038/nrd2926. Review.

15.

Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.

Huang J, Wu S, Wu CL, Manning BD.

Cancer Res. 2009 Aug 1;69(15):6107-14. doi: 10.1158/0008-5472.CAN-09-0975. Epub 2009 Jul 14.

16.

Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.

Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B, Kim J, Verheijen J, Curran K, Malwitz DJ, Cole DC, Ellingboe J, Ayral-Kaloustian S, Mansour TS, Gibbons JJ, Abraham RT, Nowak P, Zask A.

Cancer Res. 2009 Aug 1;69(15):6232-40. doi: 10.1158/0008-5472.CAN-09-0299. Epub 2009 Jul 7.

17.

AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.

Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, Sandy P, Hoersch S, Sheng Q, Gupta PB, Boehm JS, Reiling JH, Silver S, Lu Y, Stemke-Hale K, Dutta B, Joy C, Sahin AA, Gonzalez-Angulo AM, Lluch A, Rameh LE, Jacks T, Root DE, Lander ES, Mills GB, Hahn WC, Sellers WR, Garraway LA.

Cancer Cell. 2009 Jul 7;16(1):21-32. doi: 10.1016/j.ccr.2009.04.012.

18.

mTOR complex 2 in adipose tissue negatively controls whole-body growth.

Cybulski N, Polak P, Auwerx J, Rüegg MA, Hall MN.

Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9902-7. doi: 10.1073/pnas.0811321106. Epub 2009 Jun 3.

19.

Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth.

Acosta-Jaquez HA, Keller JA, Foster KG, Ekim B, Soliman GA, Feener EP, Ballif BA, Fingar DC.

Mol Cell Biol. 2009 Aug;29(15):4308-24. doi: 10.1128/MCB.01665-08. Epub 2009 Jun 1.

20.

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival.

Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS, Sabatini DM.

Cell. 2009 May 29;137(5):873-86. doi: 10.1016/j.cell.2009.03.046. Epub 2009 May 14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk